Natco Pharma Kothur facility gets USFDA warning letter
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-04-09 08:57 GMT | Update On 2024-04-09 14:27 GMT
Advertisement
Hyderabad: Natco Pharma has received a Warning Letter from the United States Food and Drug Administration (USFDA) for its Pharma Division located in Kothur Hyderabad, India.
In October, the Company received eight observations from the USFDA for the said facility after the inspection.
Read also: USFDA inspection: Natco Pharma gets 8 observations for Hyderabad Pharma Division
Now, according to BSE filing, Natco Pharma stated, "The Company does not believe that the Warning Letter will have an impact on disruption of supplies or existing revenues from this facility. It may cause delay/withholding of pending product approvals from this site".
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.